FDA Grants Fast Track to Immutep’s Eftilagimod Alpha Combo for NSCLC

The FDA has granted a Fast Track designation to Immutep’s eftilagimod alpha in combination with pembrolizumab for treatment of first-line nonsmall-cell lung cancer (NSCLC).

Eftilagimod alpha targets LAG-3, a gene that codes a protein that is involved in the regulation of the immune system. It activates both the innate and adaptive immune system to target solid tumors.

The investigational drug offers a chemotherapy-free option for patients with NSCLC, the company said.

The drug has also received Fast Track status for the treatment of patients with first-line recurrent or metastatic head and neck squamous cell carcinoma.